United BioSource Corporation (UBC; Bethesda, MD) announced the opening of its newest global office in Tokyo, Japan. The office will be led by Kumpei Kobayashi, PharmD, a biopharmaceutical industry veteran with over 20 years of product development experience throughout the Asia-Pacific region. Personnel in the new UBC office will support the company’s investigator training and certification solutions as well as ongoing clinical research monitoring services in the region.
“The UBC office in Tokyo will help us support our clients’ research projects with local personnel who understand the needs of patients, health care professionals and regulators in this important region. Local knowledge of the Asia-Pacific markets is absolutely essential when we help clients manage research projects that are often very large, complex and supported by significant financial investments,” said Catherine Spear, UBC’s Senior Vice President.
Dr. Kobayashi will be joined by several members of UBC’s management team, including David Miller, MD, who has served as a scientific leader on several Pan-Asian and multi-national studies involving sites in Japan, Taiwan, Korea, China, Hong Kong, India, Philippines, Singapore, and Thailand.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
The State of the Opioid Epidemic
March 26th 2024In part 1 of this video interview, Greg Sturmer, co-founder and CEO of Elysium Therapeutics discusses the current state of opioid usage including how pain treatment is often mismanaged and how the industry can adopt greater safety standards in developing pain therapies.